Status:
COMPLETED
Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis
Lead Sponsor:
Pfizer
Conditions:
Spondylitis, Ankylosing
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
To compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac for the treatment of ankylosing spondylitis
Eligibility Criteria
Inclusion
- Diagnosis of ankylosing spondylitis defined according to modified New York criteria, and with axial involvement
- Requiring daily treatment with nonsteroidal anti-inflammatory drugs during the previous 30 days
Exclusion
- Patients with inflammatory enterophathy, and with extra-articular manifestations
- Patients with known vertebral compression
- Received corticosteroids 6 weeks prior to the baseline visit; patients on stable dose of prednisolone equivalents ≤ 10 mg/ day for at least 14 days before randomization were permitted
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
458 Patients enrolled
Trial Details
Trial ID
NCT00648141
Start Date
January 1 2003
End Date
January 1 2005
Last Update
April 10 2008
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Aachen, Germany, 52064
2
Pfizer Investigational Site
Bad Aibling, Germany, 83043
3
Pfizer Investigational Site
Bad Iburg, Germany, 49186
4
Pfizer Investigational Site
Bad Münder am Deister, Germany, 31848